Highlights of AIDS 2014
Source: 20th International AIDS Conference (AIDS 2014)*

Module

In this Expert Analysis, David A. Cooper, MD, DSc, and Joel E. Gallant, MD, MPH, provide a comprehensive review of the most clinically significant new data from the 2014 International AIDS Conference, along with downloadable slides.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate results from recent clinical trials into management strategies for treatment-naive and treatment-experienced patients
  • Apply the latest data from studies of pre-exposure prophylaxis
  • Critically appraise new findings from studies of novel HCV regimens in HIV/HCV-coinfected patients

Topics covered include:

  • Highlights From IAC 2014
  • IAS-USA 2014 Guidelines on ART
  • MODERN: Maraviroc QD + Darunavir/RTV as First-line ART
  • OLE: Simplification to Dual ART With LPV/RTV + 3TC or FTC in Suppressed Patients
  • Virologic Outcomes on Second-line Therapy
  • Outcomes Following Virologic Suppression < 20 copies/mL
  • Use of PrEP for Prevention of HIV Acquisition
  • Risk of Cardiovascular Disease and Diabetes Following ART Initiation
  • Use of DAAs in Patients With HIV/HCV Coinfection
  • Conclusions
 

Faculty

  • David A. Cooper
    MD, DSc
    Joel E. Gallant
    MD, MPH

Credit Information

  • Release Date:
    October 13, 2014
  • Expiration Date:
    October 12, 2015
  • Physicians:
    maximum of 1.25 AMA PRA Category 1 Credits

Information on this Educational Activity

Disclosure of Conflicts of Interest

The Annenberg Center assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Faculty

David A. Cooper, MD, DSc


Director, Kirby Institute
University of New South Wales
Sydney, Australia

David A. Cooper, MD, DSc, has disclosed that he has received consulting fees from Gilead Sciences, Janssen, Merck, and ViiV and funds for research support from AbbVie, Gilead Sciences, and Merck.
 

Joel E. Gallant, MD, MPH


Associate Medical Director of Specialty Services
Southwest CARE Center
Santa Fe, New Mexico
Adjunct Professor of Medicine
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Joel E. Gallant, MD, MPH, has disclosed that he has received consulting fees from Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Takara Bio and funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Merck, Sangamo Biosciences, Vertex, and ViiV.
 

Staff

Anna Poppa, 


Editorial Contributor

Anna Poppa has no significant financial relationships to disclose.
 

Kiran Mir-Hudgeons, PhD


Clinical Editor

Kiran Mir-Hudgeons, PhD, has no significant financial relationships to disclose.
 

Jenny Schulz, PhD


Editorial Director, Virology & Other Therapeutic Areas

Jenny Schulz, PhD, has no significant financial relationships to disclose.
 

Edward King, MA


Chief Innovation Officer

Edward King, MA, has no significant financial relationships to disclose.
 

Jennifer M. Blanchette, PhD


Associate Managing Editor

Jennifer M. Blanchette, PhD, has no significant financial relationships to disclose.
 

Elaine P. Seeskin, 


Senior Managing Editor

Elaine P. Seeskin, has no significant financial relationships to disclose.
 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CCMEP; and Jan Schultz, RN, MSN, CCMEP hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Charles E. Willis, MBA, disclosed that he consults for Pfizer, Inc.

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Annenberg Center, Postgraduate Institute for Medicine (PIM), Clinical Care Options, and activity supporters do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the Annenberg Center, PIM, Clinical Care Options, and activity supporters. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

 

Target Audience

This activity is intended for physicians and other healthcare professionals involved in the care of HIV-infected patients.


Goal

The goal of this activity is to improve participants’ competence in translating the most clinically significant and relevant data from AIDS 2014 into practical management strategies for HIV-infected patients.


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate results from recent clinical trials into management strategies for treatment-naive and treatment-experienced patients
  • Apply the latest data from studies of pre-exposure prophylaxis
  • Critically appraise new findings from studies of novel HCV regimens in HIV/HCV-coinfected patients
 

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC. The Annenberg Center for Health Sciences at Eisenhower is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Commercial Support


This program is supported by educational grants from Gilead Sciences, and ViiV Healthcare.

 

Program Medium


This program has been made available online.

 

Site Requirements


  • Internet Explorer 7+, Firefox 3+, Safari 3+, or Chrome
  • JavaScript enabled
  • 1024x768+ screen resolution
  • Adobe Flash Player
 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from October 13, 2014, through October 12, 2015:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 70% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME activities completed can be found on the "CME Manager" page. There are no costs/fees for this activity.

  • How New Data From CROI 2017 May Inform Switch Strategies in HIV-Infected Patients With Poor Bone Health

    Charles B. Hicks MD - 4/21/2017    
    Is switching TDF to TAF justified in osteopenic women?
  • How New Data From CROI 2017 May Inform Treatment Simplification Options

    Charles B. Hicks MD - 4/20/2017    
    Is the switch to a 2-drug regimen in virologically suppressed HIV-infected patients feasible?
  • Optimal ART During Late Pregnancy After a Break in Therapy

    Kathleen E. Squires MD - 4/20/2017    
    Which regimen may work best during the third trimester?
  • The Promise of Long-Acting Injectable Antiretroviral Therapies

    Paul E. Sax MD - 4/12/2017    
    Will long-acting cabotegravir plus rilpivirine injections satisfy patient desire for less frequent dosing? Here is my take.
  • How New Data From CROI 2017 May Renew Interest in NNRTIs

    Charles B. Hicks MD - 4/21/2017    
    How do phase III data on doravirine affect the potential for future therapy with NNRTIs?